While the predictive and prognostic significance of KRAS and BRAF mutations in metastatic colorectal cancer (mCRC) is well established, their impact on localized colorectal cancer (CRC) remains not fully elucidated. This evidence concerns the gene BRAF and colorectal carcinoma.